{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05215574",
            "orgStudyIdInfo": {
                "id": "831-IO-101"
            },
            "secondaryIdInfos": [
                {
                    "id": "KEYNOTE-E13",
                    "type": "OTHER",
                    "domain": "MK-3475-E13 Merck Sharp & Dohme LLC."
                }
            ],
            "organization": {
                "fullName": "NGM Biopharmaceuticals, Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
            "officialTitle": "A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "study-of-as-monotherapy-and-in-combination-with-pembrolizumab-or-pembrolizumab-and-in-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-31",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-19",
            "studyFirstSubmitQcDate": "2022-01-19",
            "studyFirstPostDateStruct": {
                "date": "2022-01-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-12",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NGM Biopharmaceuticals, Inc",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors"
        },
        "conditionsModule": {
            "conditions": [
                "Pancreatic Cancer",
                "Breast Cancer",
                "Gastric Cancer",
                "Non-small Cell Lung Cancer",
                "Cervical Cancer",
                "Endocervical Cancer",
                "Squamous Cell Carcinoma of Head and Neck",
                "Bladder Urothelial Cancer",
                "Colorectal Carcinoma",
                "Esophageal Cancer",
                "Ovarian Cancer",
                "Renal Cell Carcinoma",
                "Prostate Cancer",
                "Melanoma",
                "Mesothelioma",
                "Cholangiocarcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 130,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NGM831 Monotherapy Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1a Single Agent Dose Escalation",
                    "interventionNames": [
                        "Drug: NGM831"
                    ]
                },
                {
                    "label": "NGM831 combination dose finding with pembrolizumab (KEYTRUDA\u00ae)",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1b NGM831 plus pembrolizumab (KEYTRUDA\u00ae)",
                    "interventionNames": [
                        "Drug: NGM831 plus pembrolizumab (KEYTRUDA\u00ae)"
                    ]
                },
                {
                    "label": "NGM831 and NGM438 Combination Dose Finding with pembrolizumab (KEYTRUDA\u00ae)",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1c NGM831 and NGM438 plus pembrolizumab (KEYTRUDA\u00ae)",
                    "interventionNames": [
                        "Drug: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA\u00ae)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "NGM831",
                    "description": "Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.",
                    "armGroupLabels": [
                        "NGM831 Monotherapy Dose Escalation"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "NGM831 plus pembrolizumab (KEYTRUDA\u00ae)",
                    "description": "Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.\n\nDrug: pembrolizumab (KEYTRUDA\u00ae) pembrolizumab (KEYTRUDA\u00ae) will be administered intravenously (IV) every 3 weeks in a 21day cycle.",
                    "armGroupLabels": [
                        "NGM831 combination dose finding with pembrolizumab (KEYTRUDA\u00ae)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "NGM831 and NGM438 plus pembrolizumab (KEYTRUDA\u00ae)",
                    "description": "Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.\n\nDrug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.\n\nDrug: pembrolizumab (KEYTRUDA\u00ae) pembrolizumab (KEYTRUDA\u00ae) will be administered intravenously (IV) every 3 weeks in a 21-day cycle.",
                    "armGroupLabels": [
                        "NGM831 and NGM438 Combination Dose Finding with pembrolizumab (KEYTRUDA\u00ae)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Patients with Dose-limiting Toxicities",
                    "description": "A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0 and is considered by the Investigator to be clinically relevant and attributed to the study treatment during the first 21 days after the first dose of study treatment.",
                    "timeFrame": "Baseline up to 21 Days"
                },
                {
                    "measure": "Incidence of Adverse Events",
                    "description": "Number of patients with treatment-emergent adverse events (AEs) An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of patients who experience at least one AE will be presented.",
                    "timeFrame": "Baseline up to Approximately 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum Observed Serum Concentration (Cmax) of NGM831",
                    "description": "Cmax is defined as the observed maximum serum concentration post drug administration.\n\nWill be measured for Cycle 1 and Cycle 3.",
                    "timeFrame": "Baseline up to approximately 9 weeks"
                },
                {
                    "measure": "Time to Maximum Observed Serum Concentration (Tmax) of NGM831",
                    "description": "Tmax is defined as the time to reach the observed maximum serum concentration (Cmax) post drug administration.\n\nWill be measured for Cycle 1 and Cycle 3.",
                    "timeFrame": "Baseline up to approximately 9 weeks"
                },
                {
                    "measure": "Area Under the Concentration Time Curve of the dosing interval (AUC) of Serum NGM831",
                    "description": "AUC is defined as area under the concentration time curve of the dosing interval post drug administration.\n\nWill be calculated for Cycle 1 and Cycle 3.",
                    "timeFrame": "Baseline up to approximately 9 weeks"
                },
                {
                    "measure": "Maximum Observed Serum Concentration (Cmax) of NGM438",
                    "description": "Cmax is defined as the observed maximum serum concentration post drug administration.Will be measured for Cycle 1 and Cycle 3.",
                    "timeFrame": "Baseline up to approximately 9 weeks"
                },
                {
                    "measure": "Time to Maximum Observed Serum Concentration (Tmax) of NGM438.",
                    "description": "Tmax is defined as the time to reach the observed maximum serum concentration (Cmax) post drug administration.\n\nWill be measured for Cycle 1 and Cycle 3.",
                    "timeFrame": "Baseline up to approximately 9 weeks"
                },
                {
                    "measure": "Area Under the Concentration Time Curve of the dosing interval (AUC) of Serum NGM438",
                    "description": "AUC is defined as area under the concentration time curve of the dosing interval post drug administration.\n\nWill be calculated for Cycle 1 and Cycle 3.",
                    "timeFrame": "Baseline up to approximately 9 weeks"
                },
                {
                    "measure": "Anti-drug Antibodies (ADA) Against NGM831",
                    "description": "Incidence and titers of anti-drug antibodies (ADA) against NGM831. Will be measured on Day 1 of each cycle.",
                    "timeFrame": "Baseline up to approximately 24 months"
                },
                {
                    "measure": "Anti-drug Antibodies (ADA) Against NGM438",
                    "description": "Incidence and titers of anti-drug antibodies (ADA) against NGM438. Will be measured on Day 1 of each cycle.",
                    "timeFrame": "Baseline up to approximately 24 months"
                },
                {
                    "measure": "Neutralizing antibodies (nAb) against NGM831",
                    "description": "Incidence and titers of neutralizing antibodies (nAb) against NGM831. Will be measured on Day 1 of each cycle.",
                    "timeFrame": "Baseline up to approximately 24 months"
                },
                {
                    "measure": "Neutralizing antibodies (nAb) against NGM438",
                    "description": "Incidence and titers of neutralizing antibodies (nAb) against NGM438. Will be measured on Day 1 of each cycle.",
                    "timeFrame": "Baseline up to approximately 24 months"
                },
                {
                    "measure": "Number of Patients with Objective Responses",
                    "description": "Objective Response Rate is defined as the proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) divided by the total number of evaluable patients per RECIST v1.1.",
                    "timeFrame": "Baseline up to approximately 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.\n* Adequate bone marrow, kidney and liver function\n* Performance status of 0 or 1.\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.\n\nExclusion Criteria:\n\n* Prior treatment targeting ILT3.\n* Prior treatment targeting LAIR1.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "NGM Medical Director",
                    "role": "CONTACT",
                    "phone": "(650) 243-5555",
                    "email": "NGM831@ngmbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Gilbert",
                    "state": "Arizona",
                    "zip": "85234",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 021",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.35283,
                        "lon": -111.78903
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90025",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 022",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 009",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 024",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 003",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 023",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 025",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "TERMINATED",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "NGM Clinical Study Site",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "NGM Site 001",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000018281",
                    "term": "Cholangiocarcinoma"
                },
                {
                    "id": "D000008654",
                    "term": "Mesothelioma"
                },
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                },
                {
                    "id": "D000000236",
                    "term": "Adenoma"
                },
                {
                    "id": "D000018301",
                    "term": "Neoplasms, Mesothelial"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Squamous Cell Carcinoma of Head and Neck",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M20426",
                    "name": "Cholangiocarcinoma",
                    "asFound": "Cholangiocarcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11634",
                    "name": "Mesothelioma",
                    "asFound": "Mesothelioma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2537",
                    "name": "Mesothelioma, Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M3591",
                    "name": "Adenoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20445",
                    "name": "Neoplasms, Mesothelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "asFound": "Renal Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1341",
                    "name": "Clear Cell Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "asFound": "Esophageal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T755",
                    "name": "Bile Duct Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T3584",
                    "name": "Malignant Mesothelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}